Axogen, Inc. · NASDAQ (us_market)
Healthcare · Medical Devices · United States
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-02-23$35.38 RISE2026-03-06$28.55 PEAK2026-05-05$43.74 71d | -19.3% 11d | Missed | Missed | — | — | +53.2% 60d | Missed |
DROP2025-02-25$20.11 RISE2025-06-18$9.29 PEAK2025-09-11$16.80 198d | -53.8% 113d | Missed | Missed | — | — | +80.8% 85d | Missed |
DROP2024-11-06$15.33 RISE2024-11-14$12.47 PEAK2025-01-21$18.97 76d | -18.7% 8d | Missed | Missed | — | — | +52.1% 68d | Missed |
DROP2024-03-01$10.69 RISE2024-05-06$5.67 PEAK2024-07-17$9.48 138d | -47.0% 66d | Missed | Missed | — | — | +67.2% 72d | Missed |
DROP2023-07-12$9.26 RISE2023-11-01$3.61 PEAK2024-01-29$9.68 201d | -61.0% 112d | Missed | Missed | — | — | +168.1% 89d | Missed |
DROP2022-11-10$13.09 RISE2023-03-13$7.53 PEAK2023-04-13$10.38 154d | -42.5% 123d | Missed | Missed | — | — | +37.8% 31d | Missed |
DROP2022-11-10$13.09 RISE2022-12-27$9.44 PEAK2023-01-23$10.95 74d | -27.9% 47d | Missed | Missed | — | — | +16.0% 27d | Missed |
DROP2022-08-16$11.18 RISE2022-08-29$8.87 PEAK2022-11-10$13.09 86d | -20.7% 13d | Missed | Missed | — | — | +47.6% 73d | Missed |
DROP2022-05-20$10.00 RISE2022-06-16$7.79 PEAK2022-09-09$11.50 112d | -22.1% 27d | Missed | Missed | — | — | +47.6% 85d | Missed |
DROP2022-01-06$10.70 RISE2022-04-18$6.99 PEAK2022-05-20$10.00 134d | -34.7% 102d | Missed | Missed | — | — | +43.1% 32d | Missed |
DROP2021-11-03$15.60 RISE2022-02-22$7.26 PEAK2022-05-17$9.94 195d | -53.5% 111d | Missed | Missed | — | — | +36.9% 84d | Missed |
DROP2021-08-09$17.97 RISE2021-12-15$8.80 PEAK2022-01-06$10.70 150d | -51.0% 128d | Missed | Missed | — | — | +21.6% 22d | Missed |
DROP2021-05-07$23.50 RISE2021-08-18$15.23 PEAK2021-09-02$17.66 118d | -35.2% 103d | Missed | Missed | — | — | +16.0% 15d | Missed |
DROP2021-05-07$23.50 RISE2021-06-03$18.90 PEAK2021-06-24$22.14 48d | -19.6% 27d | Missed | Missed | — | — | +17.1% 21d | Missed |
DROP2021-03-01$22.60 RISE2021-04-19$17.80 PEAK2021-05-07$23.50 67d | -21.2% 49d | Missed | Missed | — | — | +32.0% 18d | Missed |
1–15 / 19 1 / 2 | |||||||
No scored news yet for a sentiment trend.
AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified. Speaking during a company event, Dale said he w
AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified. Speaking during a company event, Dale said he w
Axogen, Inc. (AXGN) Bank of America Global Healthcare Conference 2026 May 13, 2026 12:35 PM EDTCompany ParticipantsMichael Dale - President, CEO &...
Presenter SpeechMichael Dale [Audio Gap] value proposition forward. And when I was first learned about approach and learned about Axogen I was able to quickly conclude that the purpose of the
MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced a comprehensive board refreshment plan designed to support the Company’s next phase of commercial growth and operational excellence. In a unanimous decision by the current seven-member Board of Directors, four respected directors have agreed to step down following the Company’s 2026 Annual
Shareholders of Axogen, Inc. ( NASDAQ:AXGN ) will be pleased this week, given that the stock price is up 12% to...
Shareholders of Axogen, Inc. ( NASDAQ:AXGN ) will be pleased this week, given that the stock price is up 12% to...
ALACHUA, Fla. and TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that the company will be participating in the upcoming 2026 Bank of America Global Healthcare Conference. Axogen’s management is scheduled to present on Wednesday, May 13, 2026, at 9:35 AM PT. Interested parties may access a live audio webcast of the presentation b
Citizens analyst David Turkaly maintains Axogen (NASDAQ:AXGN) with a Market Outperform and raises the price target from $42 to $50.
Wells Fargo analyst Larry Biegelsen maintains Axogen (NASDAQ:AXGN) with a Overweight and raises the price target from $40 to $48.
HC Wainwright & Co. analyst Yi Chen maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $39 to $50.
Axogen Inc (AXGN) reports a robust 26.6% revenue increase in Q1 2026, despite facing higher operating costs and a significant net loss.
Axogen Inc (AXGN) reports a robust 26.6% revenue increase in Q1 2026, despite facing higher operating costs and a significant net loss.
Health care stocks edged up late Tuesday afternoon, with the NYSE Health Care Index fractionally hig
Health care stocks edged up late Tuesday afternoon, with the NYSE Health Care Index fractionally hig
Lindsey will then provide details on financial performance, guidance and overall outlook for the year. Today's call and presentation is being broadcast live via webcast, which is available on the Investors section of AxoGen's website. Before we get started, I'd like to remind you that during the conference call, the company will make projections and forward-looking statements.
Lindsey will then provide details on financial performance, guidance and overall outlook for the year. Today's call and presentation is being broadcast live via webcast, which is available on the Investors section of AxoGen's website. Before we get started, I'd like to remind you that during the conference call, the company will make projections and forward-looking statements.
Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer; and Jens Kemp, Chief Marketing Officer. Michael will discuss first quarter 2025 financial results and corporate highlights. Today's call is being broadcast live via webcast, which is available on the Investors section of Axogen's website.
Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer; and Jens Kemp, Chief Marketing Officer. Michael will discuss first quarter 2025 financial results and corporate highlights. Today's call is being broadcast live via webcast, which is available on the Investors section of Axogen's website.
Axogen, Inc. (AXGN) Q1 2026 Earnings Call April 28, 2026 8:00 AM EDTCompany ParticipantsMichael Dale - President, CEO & DirectorLindsey Hartley - Chief...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AXGN | -8.78% | +28.81% | +20.62% | +262.53% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -11.75% | +34.52% | +24.07% | +249.85% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 1.31M | $43.53M | 0.00% | Added+655.2% | 2026-03-31 |
| StateStreet | passive | 1.15M | $37.98M | 0.00% | Added+6.6% | 2026-03-31 |
| Wellington | fundamental | 964.6K | $31.96M | 0.01% | New | 2026-03-31 |
| TwoSigma | quant | 682.1K | $22.60M | 0.02% | Added+57.4% | 2026-03-31 |
| DEShaw | quant | 265.0K | $8.78M | 0.01% | Added+64.8% | 2026-03-31 |
| Citadel | multi-strat | 202.4K | $6.70M | 0.01% | New | 2026-03-31 |
| TRowePrice | fundamental | 50.8K | $1.68K | 0.00% | Added+16.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04upcoming | 0.12 | — | — |
| 2026-04-28 | 0.07 | 0.07 | -2.00% |
| 2026-02-24 | 0.10 | 0.07 | -27.94% |
| 2025-10-29 | 0.07 | 0.12 | +76.47% |
| 2025-08-05 | 0.06 | 0.12 | +100.00% |
| 2025-05-08 | 0.02 | -0.02 | -225.00% |
| 2025-02-25 | 0.04 | 0.07 | +94.44% |
| 2024-11-07 | -0.09 | -0.04 | +57.89% |
| 2024-08-08 | -0.04 | 0.05 | +219.05% |
| 2024-05-02 | -0.07 | -0.06 | +11.76% |
| 2024-03-05 | -0.08 | -0.06 | +28.57% |
| 2023-11-07 | -0.06 | 0.01 | +115.63% |
| 2023-08-07 | -0.12 | -0.03 | +75.41% |
| 2023-05-09 | -0.14 | -0.10 | +29.58% |
| 2023-03-14 | -0.11 | -0.03 | +73.33% |
| 2022-11-08 | -0.12 | -0.01 | +91.84% |